Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma
Yen‐Shen Lu, Yoko Kashida, Samuel K. Kulp, Yu‐Chieh Wang, Dasheng Wang, Jui‐Hsiang Hung, Monica Tang, Zhong‐Zhe Lin, Te‐Jung Chen, Ann‐Lii Cheng, Ching‐Shih Chen – 25 July 2007 – Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, yet effective therapeutic options for advanced HCC are limited. This study was aimed at assessing the antitumor effect of a novel phenylbutyrate‐derived histone deacetylase (HDAC) inhibitor, OSU‐HDAC42, vis‐à‐vis suberoylanilide hydroxamic acid (SAHA), in in vitro and in vivo models of human HCC.